• Explore /
  • Poster
  • / Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.

Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.

Abstract Poster

Authors

null

Chun Loo Gan

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

Chun Loo Gan , Shaan Dudani , Connor Wells , Ziad Bakouny , Nazli Dizman , Sumanta K. Pal , Bernadett Szabados , Lori Wood , Christian K. Kollmannsberger , Neeraj Agarwal , Frede Donskov , Naveen S. Basappa , Georg A. Bjarnason , Francis Parnis , Camillo Porta , Ian D. Davis , Ulka N. Vaishampayan , Ravindran Kanesvaran , Toni K. Choueiri , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5070)

DOI

10.1200/JCO.2020.38.15_suppl.5070

Abstract #

5070

Poster Bd #

139

Abstract Disclosures

Similar Posters

First Author: Ana-Alicia Beltran-Bless

First Author: Kathryn Fortune

First Author: Georges Gebrael

First Author: Connor Wells